cas 210169-05-4|| where to buy 5-fluoropyridin-3-amine

Nombre del producto:5-fluoropyridin-3-amine

IUPAC Name:5-fluoropyridin-3-amine

Unidad de embalaje	Stock disponible	Precio($)
CM104091-25g	in stock	Ǻș
CM104091-100g	in stock	ƻŭƅ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 210169-05-4 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :210169-05-4; Fórmula molecular:C5H5FN2; Punto de fusión:-; Código de sonrisas:NC1=CC(F)=CN=C1; Densidad:

: Número de catálogo:CM104091; Peso molecular:112.11; Punto de ebullición:232.7°C at 760 mmHg; Nº Mdl:MFCD00234073; Almacenamiento:Keep in dark place, store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Ivosidenib; Tibsovo (ivosidenib tablets) is a precision medicine that targets a specific type of mutation known as isocitrate dehydrogenase 1 (IDH1). Tibsovo is approved in five indications globally, including approvals in the U.S., European Union, Australia, and China.
Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation.
Fifth approved indication for Tibsovo solidifies Servier’s leadership in mutant IDH inhibition.